Model-based Bayesian adaptive dose-finding designs for a phase II trial

Statistics in Biopharmaceutical Research

Volumn 3, Issue 2, 2011, Pages 276-287

  Jones, Byron ^a   Layton, Gary ^a   Richardson, Helen ^a   Thomas, Neal ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Bayesian analysis; Clinical trial; Dose finding; Emax modeling; Phase II

Indexed keywords

NEW DRUG; PLACEBO;

ARTICLE; BAYES THEOREM; CONFIDENCE INTERVAL; DECISION MAKING; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MAXIMUM LIKELIHOOD METHOD; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); SAMPLE SIZE; SIMULATION; STATISTICAL DISTRIBUTION; STUDY DESIGN;

EID: 84867120289     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1198/sbr.2011.10035     Document Type: Article

References (8)

1. Dette, H., Bretz, F., Pepelyshev, A., and Pinheiro, J. (2008), "Optimal Designs for Dose-Finding Studies, " Journal of the American Statistical Association, 103, 1225-1237. 279
2. Dragalin, V. (2007), "Guest Editorial-Statistical Issues in Adaptive Design Methods in Clinical Trials, " Journal of Biopharmaceutical Statistics, 17, 955-956. 277
3. Holford, N., and Sheiner, L. (1981), "Understanding the DoseResponse Relationship: Clinical Application of PharmacokineticPharmacodynamic Models, " Clinical Pharmacokinetics, 6, 429-453. 276
4. Iliadis, A., and Macheras, P. (2006), Modeling in Biopharmaceutics, and Pharmacodynamics: Homogeneous and Heterogeneous Approaches, Springer: New York. 276
5. Lunn, D., Spiegelhalter, D., Thomas, A., and Best, N. (2009), "The BUGS project: Evolution, Critique, and Future Directions, " Statistics in Medicine, 28, 3049-3067. 278
6. Mandema, J., Hermann, D., Wang, W., Sheiner, T., Milad, M., BakkerArkema, R., and Hartman, D. (2005), "Model-Based Development of Gemcabene, A New Lipid-Altering Agent, " The AAPS Journal, 7, E513-E522. 278
7. Miller, F., Guilbaud, O., and Dette, H. (2007), "Optimal Designs for Estimating the Interesting Part of a Dose-Effect Curve, " Journal of Biopharmaceutical Statistics, 17, 1097-1115. 287
8. Thomas, N. (2006), "Hypothesis Testing and Bayesian Estimation Using a Sigmoid Emax Model Applied to Sparse Dose-Response Designs, " Journal of Biopharmaceutical Statistics, 16, 657-677. 280